Avadel Pharmaceuticals plc (AVDL)

17.81 -0.01 (-0.06%) At close: 04:00PM EDT

Avadel Pharmaceuticals plc

10 Earlsfort Terrace
Dublin 2
Ireland
353 1 901 5201
https://www.avadel.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 154

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gregory J. Divis Jr.	CEO & Director	753.69k	N/A	1967
Mr. Thomas S. McHugh	Senior VP, Principal Financial and Accounting Officer & CFO	526k	N/A	1965
Mr. Richard J. Kim	Chief Commercial Officer	548.44k	N/A	1969
Mr. Jerad G. Seurer	General Counsel & Company Secretary	N/A	N/A	N/A
Mr. Gregory J. Davis	VP of Corporate and Business Development	N/A	N/A	1965
Mr. Mark W. Elrod	Vice President of Sales	N/A	N/A	N/A
Ms. Angie Woods	Vice President of People & Culture	N/A	N/A	N/A
Dr. Jordan S. Dubow M.D.	Consultant	727.93k	395.25k	1979
Dr. Jason M. Vaughn	Senior Vice President of Technical Operations	N/A	N/A	N/A
Ms. Jennifer Gudeman PharmD	Senior Vice President of Medical & Clinical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Corporate governance

Avadel Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.